Literature DB >> 10541392

Radiologic findings of bronchogenic carcinoma with pulmonary metastases at presentation.

E M Marom1, E F Patz, S J Swensen.   

Abstract

PURPOSE: To describe the radiologic findings in patients with primary bronchogenic carcinoma and pulmonary metastases at presentation.
MATERIALS AND METHODS: A retrospective review of patients with bronchogenic carcinoma who at presentation had pulmonary metastases.
RESULTS: Fourteen (52%) men and 13 (48%) women with a mean age of 60 years were identified. Adenocarcinoma was the most common histology (70%). The number of nodules varied, although 78% of patients had greater than 50 nodules. Nodules size ranged from 2 to 30 mm, but 82% of patients had nodules less than 10 mm in diameter. Mediastinal lymphadenopathy was seen in 41% of patients, and pleural disease in 44% of patients. Only 37% had radiologic evidence of extrathoracic disease, with bone metastases (30%) being the most common.
CONCLUSION: Multiple pulmonary nodules may be the presenting thoracic manifestation of primary bronchogenic carcinoma, with patterns of metastases and survival rates similar to other stage IV patients.

Entities:  

Mesh:

Year:  1999        PMID: 10541392     DOI: 10.1016/s0009-9260(99)91088-7

Source DB:  PubMed          Journal:  Clin Radiol        ISSN: 0009-9260            Impact factor:   2.350


  2 in total

1.  The probability of malignancy in small pulmonary nodules coexisting with potentially operable lung cancer detected by CT.

Authors:  Yue Yuan; Tsuneo Matsumoto; Atsuto Hiyama; Goji Miura; Nobuyuki Tanaka; Takuya Emoto; Takeo Kawamura; Naofumi Matsunaga
Journal:  Eur Radiol       Date:  2003-05-21       Impact factor: 5.315

2.  Clinical features of lung adenocarcinomas with epidermal growth factor receptor mutations and miliary disseminated carcinomatosis.

Authors:  Hee Joung Kim; Seong Hui Kang; Hyun Woo Chung; Jong Sik Lee; Sun Jong Kim; Kwang Ha Yoo; Kye Young Lee
Journal:  Thorac Cancer       Date:  2015-02-14       Impact factor: 3.500

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.